Wang X, Rothen J, Huang S, Long JB, Soulos PR, Goldberg SB, Mamtani R, Presley CJ, Kunst N, Ma S, Wang SY, Gross CP, Dinan MA. Adoption of Broad Genomic Profiling in Patients With Cancer , JAMA Oncol: 2025
Wang X, Long JB, Rothen J, Soulos PR, Robinson TJ, Presley CJ, Goldberg SB, Mamtani R, Wang SY, Kunst N, Ma S, Huang S, Gross CP, Dinan MA. BPI25-017: A Novel Integrated Classification Schema for Molecular Findings by Potential Clinical Actionability: A Tool for Assessment of Real-World Cancer Care in the Targeted Therapy Era , J Natl Compr Canc Netw, 23: 2025
Geynisman DM, Chepynoga K, Yates G, Tate A, Kurt M, Patel MY, Teitsson S, Mitra S, Mamtani R. Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 Trial , Clin Genitourin Cancer: 2025
Mamtani R, Matsubara N, Pino AM, Herranz UA, Şendur MAN, Gravis G, Huillard O, Lee HJ, Gafanov R, Joly F, Bedke J, Sella A, Chang YH, Imai K, Moreno BH, Xu JZ, Alva A, Powles T. Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial , Clin Genitourin Cancer, 23: 2025,102248
Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C. Evolving racial/ethnic disparities in AML survival in the novel therapy era , Blood Adv, 9: 2025,533-544
Stalker M, Qu K, Cohen RB, Mamtani R, Hwang WT, Sun L. "Off-Label" Use of Checkpoint Inhibitors in Patients With Negative or Unknown PD-L1 Status in Advanced Head and Neck Cancer , J Natl Compr Canc Netw: 2025
Nishwant Swami, Wei-Ting Hwang, Ronac Mamtani, Mark O'Hara, William Chapi Real-world survival comparison of second-line treatment strategies for patients with RAS/RAF wild-type, right-sided metastatic colorectal cancer. , Journal of Clinical Oncology, 43(4_suppl): 2025,73
Orcutt X, Chen K, Mamtani R, Long Q, Parikh RB. Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations , Nat Med: 2025
Fléchon A, Morales-Barrera R, Powles T, Alva A, Özgüroğlu M, Csöszi T, Loriot Y, Rodriguez-Vida A, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Gunduz S, Mamtani R, Yu EY, Montesa Pino A, Anido U, Sendur MAN, Gravis G, Révész J, Kostorov V, Huillard O, Ma J, Rajasagi M, Vajdi A, Lunceford J, Cristescu R, Imai K, Homet Moreno B, Matsubara N. Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma , Clin Cancer Res, 30: 2024,5353-5364
Guadamuz JS, Wang X, Altomare I, Camelo Castillo W, Sarkar S, Mamtani R, Calip GS. Mediators of racial and ethnic inequities in clinical trial participation among patients with cancer, 2011-2023 , JNCI Cancer Spectr, 8(5): 2024
